论文部分内容阅读
目的观察洛伐他汀对人脐静脉内皮细胞基质金属蛋白酶9表达的影响。方法体外培养人脐静脉内皮细胞,加入20μg/L肿瘤坏死因子α诱导后,再用0.05～1.35μmol/L洛伐他汀处理0～24 h,蛋白印迹以及逆转录聚合酶链反应分别检测基质金属蛋白酶9的蛋白和mRNA表达情况,明胶酶谱法测定基质金属蛋白酶9活性。结果肿瘤坏死因子α能诱导人脐静脉内皮细胞的基质金属蛋白酶9表达和活性增强,洛伐他汀处理后,基质金属蛋白酶9的mRNA水平、蛋白量及活性均降低,且呈明显的时间和剂量依赖性,其中0.05μmol/L洛伐他汀能显著降低基质金属蛋白酶9的mRNA水平,但在蛋白水平和基质金属蛋白酶9活性上,0.05μmol/L洛伐他汀并没有表现出显著的降低效果,其余洛伐他汀各浓度均能对基质金属蛋白酶9的mRNA水平、蛋白量及活性产生显著的抑制作用,以1.35μmol/L洛伐他汀的抑制效果最显著。结论洛伐他汀能抑制肿瘤坏死因子α诱导的人脐静脉内皮细胞基质金属蛋白酶9的表达。
Objective To observe the effect of lovastatin on the expression of matrix metalloproteinase 9 in human umbilical vein endothelial cells. Methods Human umbilical vein endothelial cells were cultured in vitro. After induced by 20μg / L tumor necrosis factor α, the cells were treated with lovastatin 0.05 ~ 1.35μmol / L for 0 ~ 24 h. Western blotting and reverse transcription polymerase chain reaction Protease 9 protein and mRNA expression, gelatin zymography assay of matrix metalloproteinase 9 activity. Results Tumor necrosis factor-α (TNF-α) induced the expression and activity of MMP-9 in human umbilical vein endothelial cells. After lovastatin treatment, the mRNA and protein level and activity of MMP-9 decreased, Dependent, of which lovastatin at 0.05 μmol / L significantly decreased MMP-9 mRNA level, but lovastatin at 0.05 μmol / L showed no significant reduction in protein level and MMP-9 activity, All the other concentrations of lovastatin could significantly inhibit the expression of MMP-9 mRNA and protein, and the inhibitory effect of lovastatin at 1.35 μmol / L was the most significant. Conclusion Lovastatin can inhibit tumor necrosis factor α-induced human umbilical vein endothelial cell matrix metalloproteinase 9 expression.